Modulation of synaptic maintenance

Patent metadata

Field	Value
Publication number	US-9480658-B2
Application number	US-201213586556-A
Country	US
Kind code	B2
Filing date	Aug 15, 2012
Priority date	Dec 9, 2005
Publication date	Nov 1, 2016
Grant date	Nov 1, 2016

Abstract

C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.

First claim

What is claimed is:

1. A method of inhibiting synapse loss in a patient afflicted with a neurodegenerative disorder triggered or exacerbated by traumatic injury to the brain, the method comprising administering to the patient a therapeutic amount of a complement inhibitor to thereby treat the neurodegenerative disorder, wherein the complement inhibitor is an antibody that binds to a component of the C1 complex, wherein the component of the C1 complex is selected from the group consisting of C1q, C1s and C1r.

2. The method of claim 1 , wherein the antibody binds to C1q.

3. The method of claim 1 , wherein the antibody binds to C1s.

4. The method of claim 1 , wherein the antibody binds to C1r.

5. A method of treating a patient afflicted with a neurodegenerative disorder triggered or exacerbated by traumatic injury to the brain, the method comprising administering a therapeutic amount of a complement inhibitor to the patient to thereby treat the neurodegenerative disorder, wherein the complement inhibitor is an antibody that binds to a component of the C1 complex, wherein the component of the C1 complex is selected from the group consisting of C1q, C1s and C1r.

6. The method of claim 5 , wherein the antibody binds to C1q.

7. The method of claim 5 , wherein the antibody binds to C1s.

8. The method of claim 5 , wherein the antibody binds to C1r.

Assignees

• Barres Ben A
• Stephan Alexander H
• Stevens Beth A
• Univ Leland Stanford Junior

Inventors

• Barres Ben A
• Stephan Alexander H
• Stevens Beth A

Classifications

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• G01N33/564

  for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/727 Primary

  Heparin; Heparan · CPC title